🇺🇸 FDA
Pipeline program

Sativex®

GWMS0208

Phase 3 small_molecule completed

Quick answer

Sativex® for Detrusor Overactivity is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Detrusor Overactivity
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials